Five Regulatory Forces Reshaping the UK Reinsurance Market in 2026

Introduction

The United Kingdom enters 2026 at an interesting juncture. It is in a period of significant reform across the legal and regulatory landscape for both life and non-life reinsurance. It will be interesting to see how these reforms will impact London’s position as a insurance and reinsurance capital hub.

In respect of life reinsurance in the UK, these developments are being driven by the competitive bulk purchase annuity (BPA) market, whereby defined benefit pension schemes transfer their pension liabilities to insurance companies. In 2024, £47.8 billion of pension liabilities were transferred.¹https://www.abi.org.uk/news/blog-articles/2025/8/the-bulk-purchase-annuity-market-a-quiet-powerhouse-in-the-pensions-ecosystem/ In 2025, while the total value of insurance liabilities transferred fell, it is notable that there were a record number of transactions. Private capital is increasingly becoming a prominent factor in the BPA market, which was clearly shown in 2025/2026 as three UK BPA insurers were acquired by private capital groups with alternative asset managers. Alternative asset managers have been attracted to acquiring UK BPA insurers by the opportunity to manage the large pools of assets generated by BPA transactions.

Private capital is also a key factor in the changing legal and regulatory landscape for non-life reinsurance transactions. Typically, non-life reinsurance transactions involving private capital are driven by a demand to provide investors with access to investments in reinsurance returns that are uncorrelated with more traditional asset classes, with the potential for associated asset management mandates of lesser importance when compared with life reinsurance transactions. Over recent years, the PRA, FCA and Lloyd’s have contributed enormously to reforming the UK’s insurance sector in a way that makes the UK competitive internationally as a destination for international investment capital while maintaining the UK’s reputation for robust legal and regulatory protections for policyholders and other insurance market participants, and this reform is set to continue for some time yet.

Five regulatory developments are likely to be impactful over the course of this year.

1. ISPV Reforms and the Success of London Bridge 22

Making the ISPV Framework More Competitive: PS9/25

On 24 July 2025, the PRA delivered a significant overhaul of the UK’s Insurance Special Purpose Vehicle (ISPV) regime. Policy Statement PS9/25, which followed the CP15/24 consultation of November 2024, took immediate effect and set out a framework designed to increase the competitiveness of the ISPV regime when compared with offshore alternatives.

Four noteworthy aspects of the reforms are:

1. AMRE Flexibility. Multi-year ISPVs may now allow their aggregate maximum risk exposure (AMRE) to increase over time, tracking realised investment returns subject to a seven-year lifecycle cap. The practical effect is to remove the need for investors to inject fresh capital to cover AMRE increases.
2. Grace Period Alignment. A 30-business-day grace period has been introduced to permit ISPVs to achieve fully funded status at the start of a transaction, improving an investor’s internal rates of return.
3. Accelerated Authorisation. For standard ISPVs meeting defined criteria – non-life risk with a clearly defined loss trigger, securities placed via a syndicated arrangement underwritten on a best efforts basis, and a maximum 15-year term – the PRA’s commitment to process applications has been cut from four to six weeks to ten business days.
4. Multi-Transaction Flexibility. ISPVs may now enter into multiple risk transformation transactions under a single contractual arrangement (previously an ISPV would have to be constituted as a protected cell company (PCC) in order to achieve this). This reform materially simplifies renewals and multi-tranche transactions.

Nonetheless, the accompanying Supervisory Statement SS2/25 makes clear that, while not formally prohibited, the PRA does not expect UK firms to transfer annuity risk or equivalent risks to ISPVs. The regulator’s concern is that annuity risks would require the ISPV to hold assets with significant credit and market risk. This approach means its is not likely that the existing ISPV regime will be used by UK life insurers to raise capital. However, as we address later in this article, the PRA appeared to be more optimistic about the use of ISPV like structures to raise capital for the UK life insurance market through its publication of its discussion paper on alternative life capital, DP2/25.

London Bridge ²https://www.skadden.com/insights/publications/2025/08/pra-announces-reform-to-the-uk-insurance: Proof of Concept³https://www.artemis.bm/news/london-bridge-2-has-become-a-really-attractive-place-for-third-party-capital-turk/

Against this backdrop of structural reform, the one major success story for the UK’s ISPV regime has been the London Bridge 2 (LB2) structure. With approximately 21 separate transactions placed through LB2, as of October 2025, LB2 has facilitated the injection of over £2.2 billion⁴https://www.artemis.bm/news/london-bridge-has-supported-2-2bn-of-new-capital-entry-to-lloyds-tiernan/ in new capital to support underwriting at Lloyd’s of London.

LB2’s success shows that it is possible to develop an onshore insurance linked security framework in the UK that is competitive internationally. It remains to be seen whether the changes brought in by PS9/25 will make any material difference to the number and size of non-LB2 ISPVs in the UK.

2. A New UK Captive Regime⁵https://www.skadden.com/-/media/files/publications/2026/01/uk-prudential-regulation-authority-announces-its-2026-supervision-priorities-for-insurers/uk_prudential_regulation_authority_ announces_its_2026_supervision_priorities_for_insurers.pdf

In the Summer of 2025, the UK consulted on a new UK captive regime.⁶https://www.bankofengland.co.uk/prudential-regulation/publication/2025/july/captive-insurance-statement The PRA expects to launch the new regime in 2027.

Guernsey, the Isle of Man, Luxembourg, Bermuda and the Cayman Islands have historically dominated the captive reinsurance market.

As part of the new regime, the PRA intends to take a more proportionate approach to authorising and regulating captives, including by streamlining the authorisation process, reducing capital requirements and reducing ongoing reporting and administrative requirements compared with traditional insurers and reinsurers, reflecting the more limited and group-focused nature of their risk exposures. The government’s intention is that regulatory obligations should be proportionate to the lower level of policyholder risk typically associated with captive insurance arrangements.

The regime is also expected to distinguish between different types of captives, direct-writing captives that insure the risks of group companies and reinsurance captives that reinsure those risks. In addition, certain limitations are envisaged, including restrictions on captives writing compulsory lines of insurance on a direct basis.

A further element of the reforms is the potential use of protected cell company structures to facilitate the establishment of captives. This would allow multiple entities to operate separate captive “cells” within a single legal structure, lowering the cost and complexity of entry and enabling smaller firms to access captive insurance arrangements without establishing standalone insurers.

While the reforms proposed are welcome, it remains to be seen whether this will lead to the UK becoming a leading jurisdiction for captive insurers and reinsurers.

Lloyd’s has also emerged as an attractive jurisdiction for establishing certain types of insurance and reinsurance captives. In particular, the breadth of insurance and reinsurance licences available through the Lloyd’s market enables multinational groups to establish a Lloyd’s captive and write a greater proportion of business directly with their local subsidiaries, thereby reducing reliance on fronting insurers in local jurisdictions.

3. Alternative Life Capital: The PRA Opens the Debate⁷https://www.skadden.com/insights/publications/2025/12/the-pras-discussion-paper

Discussion Paper 2/25, published on 14 November 2025, represents the PRA’s most substantive engagement to date with the question of how capital markets might participate directly in the financing of UK life insurance risk outside traditional debt and equity markets.

The paper identifies five use cases the PRA considers worthy of development: patient asset deployment; demographic reinsurance capacity for longevity and mortality risk diversification; management of credit risk concentrations; support for bulk annuity transactions; and capital solutions for UK mutual insurers with constrained access to conventional markets.

The PRA has set out high-level considerations that frame its current thinking on how it will approach alternative life capital arrangements, including: alternative life capital structures must not reduce the quality or quantity of capital supporting insurance risks; risk transfer to capital markets must be contractually bounded and time-limited; the UK cedant must retain management of tail and residual risks at all times; and the primary effect of such structures should be capital relief not balance sheet financing.

The PRA does not intend to allow alternative life capital vehicles to benefit from the matching adjustment, (as this may be impractical and, in the PRA’s view, may lead to regulatory arbitrage).

The practical implications of this last constraint are significant. Investors are drawn to life reinsurance structures precisely because the matching adjustment enhances the return on long-duration assets. Excluding alternative life capital vehicles from this benefit materially reduces their attractiveness and risks limiting the market to a smaller pool of investors.

The PRA’s preference for structures in which assets remain on the cedant’s balance sheet, i.e. a funds-withheld arrangement in which an investor’s asset manager manages assets while they remain on the UK insurer’s balance sheet. This gives the ceding insurer, and indirectly, the PRA, greater visibility on what assets are being used to back policyholder liabilities. In our view, it appears that the PRA believes that keeping assets on the ceding insurer’s balance sheet will mean that those assets are more likely to be UK originated.

4. Funded Reinsurance: A Regulatory Reckoning⁸https://www.bankofengland.co.uk/speech/2025/september/vicky-white-speech-at-the-bank-of-america-annual-ceo-conference ⁹https://www.skadden.com/insights/publications/2025/09/pra-signals-important-change-in-approach-to-funded-re

The PRA’s Signals of Change

No single topic has been more prominent in the UK life reinsurance market during the past year than the PRA’s consideration of funded reinsurance, variously known as asset-intensive reinsurance or Funded Re. There has been regulatory engagement in the form of speeches, industry roundtables and supervisory letters, further to a published set of regulatory expectations in 2024 in the form of Supervisory Statement SS5/24. The PRA is expected to publish a further update in Q2 2026 on its policy proposals.

The PRA’s concerns are threefold. First, the PRA is concerned about potential regulatory arbitrage. Organisations including the International Monetary Fund, the Bank for International Settlements, and the UK’s Financial Policy Committee have also raised concerns of this nature. Second, systemic risk: the PRA is concerned that the collateral underpinning many Funded Re structures consists of private, complex, and illiquid assets that create concentration risks which are not immediately visible on the cedant’s balance sheet. Third, opacity: the PRA has expressed concern about cash-flow mismatches, unhedged currency exposures, and the transformation of risky or unstructured assets into apparent safety through the use of collateral.

The Unbundling Proposal

The PRA has also noted that its current principles-based approach to addressing Funded Re adopted by the setting of supervisory expectations (including those set out in Supervisory Statement SS5/24) may be insufficient to address the potential for systemic risks from widespread use of Funded Re.

The most structurally significant element of the PRA’s thinking is its suggestion that Funded Re should be decomposed, for Solvency UK balance sheet purposes, into two separate components: a collateralised loan and a longevity swap. Under current Solvency UK treatment, Funded Re is treated as an almost risk-free arrangement on the insurer’s balance sheet.¹⁰https://www.bankofengland.co.uk/-/media/boe/files/prudential-regulation/solvency-ii/funded-roundtable-1-slides.pdf A collateralised loan, by contrast, attracts capital charges reflecting credit and other risks. The PRA’s position is that these two arrangements are economically equivalent yet treated very differently under the existing rules. This differential appears to be at the heart of the PRA’s arbitrage concern. However, we should note that what may not be accounted for is that risk carriers in offshore jurisdictions hold their own capital against those risks, and as discussed below, this argument arguably disregards the concept of equivalence.

The PRA has stated that any regulatory changes are expected to apply prospectively only, with existing transactions grandfathered under current rules. For cedants who have entered into a large number of Funded Re transactions and have more in the pipeline, this has provided some reassurance. The PRA has also made clear that it does not wish to prohibit modest use of Funded Re. The PRA views a proportionate amount of Funded Re as a valuable source of patient, loss-absorbing capital.

One issue that remains unresolved concerns transactions with counterparties located in jurisdictions recognised as equivalent to Solvency UK, such as Bermuda. If the PRA were to impose additional capital requirements on funded reinsurance transactions with counterparties in equivalent jurisdictions, this could be difficult to reconcile with the principle of equivalence recognition underpinning the Solvency UK framework and making the Solvency UK regime more autarkic.

5. Sidecars: The Convergence Opportunity¹¹https://www.skadden.com/insights/publications/2026/2026-insights/sector-spotlights/as-insurance-private-capital-and-asset-management-converge ¹²https://www.skadden.com/insights/publications/2026/2026-insights/sector-spotlights/as-insurance-private-capital-and-asset-management-converge

No structural trend in the global reinsurance market better illustrates the transformation of the past decade than the explosive growth of sidecar transactions. Financial sponsors, sovereign wealth funds, family offices, and diversified investment managers have injected capital at scale into sidecar structures, seeking access to insurance risk without the friction and equity dilution of acquiring or establishing a full carrier.

In a reinsurance sidecar, the cedant identifies a block of existing business or anticipated new flow, and through a competitive or bilateral process capitalises a reinsurance vehicle, typically a segregated account company, protected cell, or fully licensed reinsurer, that accepts the risk through a reinsurance agreement. Investors are attracted by uncorrelated returns, premium float, and asset management fee income. For insurers, sidecars provide capital that does not dilute common equity and allows the insurer to benefit indirectly, through better reinsurance pricing, to asset management expertise not available to it.

2025 was another exceptionally active year for sidecar transactions globally. The drivers are structural, not cyclical: conventional capital markets have struggled to satisfy insurer capital needs at competitive cost; investors are overallocated to traditional investments; and the self-terminating nature of many non-life sidecars, with defined run-off periods of five to seven years, is highly attractive to private equity funds requiring liquidity certainty.

The UK market is more nuanced. On the non-life side, the post-PS9/25 ISPV regime and the demonstrated success of London Bridge 2 suggest that the UK can offer a credible platform for property-casualty sidecar activity, particularly through the Lloyd’s market. On the life side, the path remains obstructed. The PRA’s position that ISPVs are not appropriate vehicles for annuity risk, combined with the substantial regulatory lead time for authorising a new life reinsurance vehicle, means that the UK is simply not competitive with Bermuda for life sidecar business today.

There is strong latent demand, from both potential investors and UK life cedants, for a straightforward life sidecar pathway. The Discussion Paper on alternative life capital at least indicates that the PRA sees value in creating such a pathway. If the 2026 consultations produce a framework that permits investors to participate in defined tranches of UK life risk through a time-limited, fully funded, PRA-supervised structure, the UK could begin to capture a material share of the life sidecar business that is currently flowing to Bermuda.

The convergence of insurance, private capital, and asset management is not a cyclical phenomenon. It is a structural shift – and the UK’s ability to participate fully depends on the regulatory choices made in the next eighteen months.

Conclusion

The UK reinsurance market in 2026 presents new interesting opportunities as well as significant challenges to stakeholders. The PRA and FCA are taking significant and proportionate steps to attract investment into the UK, including by liberalising the ISPV framework, progressing a new captive regime, and consulting on alternative life capital. At the same point in time, the PRA and FCA is tightening its regulation of certain parts of the market, most notably through its reassessment of Funded Re, and the potential for further rules in this space in 2026. Progressing both approaches, without sacrificing policy coherence, will be a challenge.

The UK’s position as one of the world’s leading reinsurance centres is not seriously in doubt. What could be at stake is its position on the frontier of convergence – the space where insurance, private capital, and asset management meet, and whether the UK will have competitive legal and regulatory frameworks in place to ensure that market participants (including investors) choose the UK, while ensuring that policyholders are not only protected, but actually benefit from this convergence.